Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukocytapheresis for rheumatic disease.

Toshihiko Hidaka1, Kimihiro Suzuki

  • 1Internal Medicine I, National Defense Medical College, Tokorozawa, Saitama, Japan. kogen@me.ndmc.ac.jp

Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
|August 16, 2003
PubMed
Summary

Leukocytapheresis (LCAP) is a blood filtering treatment for rheumatic diseases. Filtration LCAP is highlighted as a simple, safe, and effective option, commonly used in Japan.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis.

Rheumatology (Oxford, England)·2026
Same author

The prevalence of pulmonary airway lesions is high in HTLV-1-positive rheumatoid arthritis: a cross-sectional observational study.

Rheumatology advances in practice·2026
Same author

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Drug discoveries & therapeutics·2026
Same author

Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment.

Rheumatology (Oxford, England)·2026
Same author

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis.

Arthritis research & therapy·2026
Same author

Treatment outcomes stratified by interferon profile and autoantibodies in rheumatoid arthritis.

Journal of autoimmunity·2025

Area of Science:

  • Rheumatology
  • Immunology
  • Medical Technology

Background:

  • Leukocytapheresis (LCAP) is an apheresis method to remove pathogenic leukocytes from blood.
  • Various LCAP techniques exist, including granulocytapheresis (GCAP) and filtration LCAP.
  • These methods are used for treating rheumatic diseases.

Purpose of the Study:

  • To review Leukocytapheresis (LCAP), specifically filtration LCAP, for treating rheumatic diseases.
  • To highlight the advantages of GCAP and filtration LCAP in clinical practice.

Main Methods:

  • Review of existing literature on LCAP in rheumatic diseases.
  • Focus on filtration LCAP and granulocytapheresis (GCAP) modalities.
  • Discussion of equipment, procedures, and adverse events.

Related Experiment Videos

Main Results:

  • GCAP and filtration LCAP are widely used in Japan.
  • These methods are favored for their simple, practical equipment and procedures.
  • Adverse events associated with GCAP and filtration LCAP are rare and minor.

Conclusions:

  • Filtration LCAP is a viable and effective treatment for rheumatic diseases.
  • The simplicity and safety profile of filtration LCAP contribute to its common use.
  • LCAP, particularly filtration LCAP, warrants consideration in the management of rheumatic conditions.